What If London Loses One Of Its Top Companies?
Pharmaceutical giant AstraZeneca Plc is currently the third-biggest company in the UK's headline FTSE 100 index by market capitalisation, if you want to be really pedantic. At this morning's prices, it accounts for around 7.28% of the entire FTSE 100, just behind banking group HSBC Holdings Plc. on 7.31%. Oil major Shell Plc leads on 7.35%.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Penrith housing development clears 'nutrient neutrality' hurdle
Story Homes and Burnetts Solicitors have secured approval for 194 new homes at The Fairways in Penrith, overcoming delays caused by nutrient neutrality requirements. The development is the first in Cumbria to secure planning permission with an associated agreement detailing the Government's Nutrient Neutrality Mitigation Scheme for housing. Robbie Mather, partner and head of commercial property at Burnetts, said: "Development in certain parts of Cumbria has stalled and there is a real need to provide all types of housing. "We have been working hard to raise concerns regarding the impact of nutrient neutrality with local councils. "I am pleased to have assisted Story Homes getting this site secured and hope this is the first of many – as there is certainly some catching up to do for housing delivery within the county." Nutrient neutrality rules require that developments do not increase nutrient pollution in nearby water catchments, particularly in areas with protected habitats already in 'unfavourable condition'. The regulations have caused significant delays to planning applications across the region. Adam McNally, senior land and planning manager for Cumbria and south west Scotland at Story Homes, praised the legal support that helped unlock the project. He said: "Burnetts provided an attentive, on-point service in the resolution of our site's highly complex planning legal agreements, which were a first of their kind for volume housebuilding involving cross local authority legal coordination. "Special thanks to Robbie for getting this over the line and enabling our start on site." A development is considered nutrient neutral when it does not add additional nutrient pollution to the environment, typically through wastewater or surface water runoff. This is achieved by designing and implementing mitigation measures as part of the development, allowing housing to proceed without harming protected habitats. The Fairways scheme is seen as a potential model for unlocking other stalled developments in Cumbria and addressing the region's housing needs.
Yahoo
32 minutes ago
- Yahoo
When Should You Buy Fresenius Medical Care AG (ETR:FME)?
Let's talk about the popular Fresenius Medical Care AG (ETR:FME). The company's shares saw a double-digit share price rise of over 10% in the past couple of months on the XTRA. While good news for shareholders, the company has traded much higher in the past year. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. However, could the stock still be trading at a relatively cheap price? Let's examine Fresenius Medical Care's valuation and outlook in more detail to determine if there's still a bargain opportunity. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The share price seems sensible at the moment according to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 22.24x is currently trading slightly above its industry peers' ratio of 22.13x, which means if you buy Fresenius Medical Care today, you'd be paying a relatively sensible price for it. And if you believe Fresenius Medical Care should be trading in this range, then there isn't really any room for the share price grow beyond the levels of other industry peers over the long-term. Furthermore, Fresenius Medical Care's share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. This may mean it is less likely for the stock to fall lower from natural market volatility, which suggests less opportunities to buy moving forward. View our latest analysis for Fresenius Medical Care Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Fresenius Medical Care's earnings over the next few years are expected to double, indicating a very optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value. Are you a shareholder? FME's optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at FME? Will you have enough confidence to invest in the company should the price drop below the industry PE ratio? Are you a potential investor? If you've been keeping an eye on FME, now may not be the most advantageous time to buy, given it is trading around industry price multiples. However, the positive outlook is encouraging for FME, which means it's worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. Diving deeper into the forecasts for Fresenius Medical Care mentioned earlier will help you understand how analysts view the stock going forward. Luckily, you can check out what analysts are forecasting by clicking here. If you are no longer interested in Fresenius Medical Care, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Morgan Stanley assumed coverage of the company's stock with an 'Equal Weight' rating and a price objective of $5, as reported by The Fly. As per the analyst, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s stock witnessed volatility because of a combination of macroeconomic factors, underperformance on initial clinical results, and uncertainty related to the valuation and revenue drivers. Furthermore, the recent pipeline prioritization and stage of clinical development for the proprietary pipeline tend to leave numerous open questions on valuation, added the firm analyst. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. However, as part of the business combination with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been proactively streamlining its portfolio, platform, and operations, making trade-offs to emphasize resources on programs having the strongest scientific rationale and highest potential for near and long-term impact. In Q1 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s total revenue, consisting mainly of revenue from collaboration agreements, came in at $15 million as compared to $14 million for Q1 2024. This was because of the timing of projects from its Sanofi, Roche and Merck KGaA, Darmstadt, Germany collaborations. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
